Previous exposure to certain antibiotics could boost the risk of infection with drug-resistant strains of a severe fungal infection. Researchers report their findings in the May 2012 issue of the journal Antimicrobial Agents ...
May 22, 2012
0
0
A newly identified defect in a DNA repair system might leave some young leukemia patients less likely to benefit from a key chemotherapy drug, possibly putting them at greater risk of relapse. The problem was identified in ...
Sep 26, 2011
1
0
Brain cancer therapy may be more effective if the expression of an iron-storing protein is decreased to enhance the action of therapeutic drugs on brain cancer cells, according to Penn State College of Medicine researchers.
Jun 2, 2011
0
0
(Medical Xpress)—Researchers from Roswell Park Cancer Institute (RPCI) have published findings from a preclinical study assessing the effectiveness of a small-molecule inhibitor, CFAK-Y15, in treating some brain cancers. ...
Dec 24, 2012
0
0
Researchers report that a patient's microbial diversity, even before they start cancer treatment, can be linked to risk of infection during induction chemotherapy. This research is presented at ASM's Interscience Conference ...
Sep 21, 2015
0
197
In the war on cancer, powerful chemotherapy agents are increasingly packaged with immunotherapy that primes a patient's immune system to better battle the disease.
Apr 17, 2017
0
2
Researchers have found a way to help make chemotherapy more effective in treating colon cancer. They identified a new pathway (RICTOR/mTORC2) as a biological target for the disease. Targeted inhibition of RICTOR or the mTORC2 ...
Jan 13, 2020
0
10
Mayo Clinic researchers have found a way to detect and eliminate potentially troublemaking stem cells to make stem cell therapy safer. Induced Pluripotent Stem cells, also known as iPS cells, are bioengineered from adult ...
Sep 27, 2012
0
0
(HealthDay)—Long-term cardiomyopathy risk varies by chemotherapy agent for childhood cancer survivors, with a decreased risk for daunorubicin versus doxorubicin, according to a study recently published in JAMA Oncology.
Mar 1, 2019
0
2
For more than a decade, oncologists using cytotoxic chemotherapy to treat patients with advanced metastatic castration-resistant prostate cancer (mCRPC) have relied on the sequential use of single agent taxanes such as docetaxel ...
May 31, 2015
0
17
